MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 12.02.2026
Eli Lilly and Company Langfristiger Schuldenstrom 2011-2026 | LLY
Langfristiger Schuldenstrom Jährlich Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 222 M | 176 M | 156 M | - | - | - | - | - | - | - | - | - | - | 11.9 M | 1.52 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.52 B | 11.9 M | 417 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
27.9 M | $ 46.2 | 4.01 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
2.13 M | $ 2.49 | 1.22 % | $ 69.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
2 K | $ 6.85 | 1.93 % | $ 196 M | USA |
 |
Galectin Therapeutics
GALT
|
22 K | $ 2.28 | 2.24 % | $ 146 M | USA |
 |
Galapagos NV
GLPG
|
1.73 M | $ 28.82 | 1.51 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.4 | 1.51 % | $ 6.83 B |  Spain |
 |
BioNTech SE
BNTX
|
45 M | $ 94.21 | -1.35 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
257 K | $ 2.37 | 20.05 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
34.4 K | $ 0.82 | 3.97 % | $ 6.82 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 76.34 | 1.45 % | $ 12.2 B | USA |
 |
INmune Bio
INMB
|
623 K | $ 1.51 | -1.95 % | $ 37.4 M | USA |
 |
Kamada Ltd.
KMDA
|
2.12 M | $ 8.31 | 1.22 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
11.9 M | $ 85.92 | 3.88 % | $ 7.26 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 23.02 | 2.98 % | $ 3.81 B | USA |
 |
Liquidia Corporation
LQDA
|
900 K | $ 41.73 | 3.97 % | $ 3.59 B | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.56 | 1.71 % | $ 5.86 M | Israel |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.14 M | $ 106.77 | 0.9 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
MannKind Corporation
MNKD
|
2.11 M | $ 3.88 | 35.49 % | $ 1.19 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
466 K | $ 0.27 | -3.84 % | $ 660 M |  Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.63 | 0.9 % | $ 3.01 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |